Wellington Management Group LLP Has $226.82 Million Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Wellington Management Group LLP lowered its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 2.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 8,975,833 shares of the biopharmaceutical company's stock after selling 267,766 shares during the period. Wellington Management Group LLP owned approximately 13.52% of Celldex Therapeutics worth $226,819,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. American Century Companies Inc. grew its position in Celldex Therapeutics by 46.5% during the 4th quarter. American Century Companies Inc. now owns 608,457 shares of the biopharmaceutical company's stock worth $15,376,000 after purchasing an additional 193,093 shares in the last quarter. Readystate Asset Management LP acquired a new stake in shares of Celldex Therapeutics in the third quarter worth $6,102,000. Sovran Advisors LLC purchased a new position in shares of Celldex Therapeutics during the fourth quarter valued at $2,867,000. Sphera Funds Management LTD. raised its position in Celldex Therapeutics by 35.5% during the third quarter. Sphera Funds Management LTD. now owns 419,103 shares of the biopharmaceutical company's stock valued at $14,245,000 after buying an additional 109,838 shares during the period. Finally, Fisher Asset Management LLC lifted its stake in Celldex Therapeutics by 20.9% in the 4th quarter. Fisher Asset Management LLC now owns 452,497 shares of the biopharmaceutical company's stock worth $11,435,000 after acquiring an additional 78,145 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. UBS Group started coverage on Celldex Therapeutics in a report on Thursday, February 13th. They issued a "buy" rating and a $44.00 target price on the stock. Cantor Fitzgerald reiterated an "overweight" rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. The Goldman Sachs Group decreased their target price on shares of Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating for the company in a research note on Monday, March 3rd. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price target on shares of Celldex Therapeutics in a research note on Friday, February 28th. Finally, Morgan Stanley started coverage on Celldex Therapeutics in a research report on Thursday, March 20th. They set an "overweight" rating and a $46.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $54.33.

Remove Ads

Celldex Therapeutics Price Performance

NASDAQ:CLDX traded down $0.05 during midday trading on Monday, reaching $15.73. The stock had a trading volume of 1,306,421 shares, compared to its average volume of 870,340. The stock has a market capitalization of $1.04 billion, a P/E ratio of -6.12 and a beta of 1.59. Celldex Therapeutics, Inc. has a 1-year low of $14.61 and a 1-year high of $47.00. The firm's fifty day simple moving average is $21.01 and its 200-day simple moving average is $25.16.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.02. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The company had revenue of $1.18 million for the quarter, compared to the consensus estimate of $1.25 million. On average, equities research analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.